07:58 AM EDT, 06/25/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) said Wednesday that Sanofi ( SNY ) will advance KT-485, its next-generation IRAK4 protein degrader, into clinical testing after preclinical studies showed improved selectivity and potency.

Sanofi ( SNY ) will not move forward with KT-474, opting for KT-485 instead, and has exercised its right to participate in the IRAK4 target under their collaboration agreement, the company said.

Kymera is eligible for up to $975 million in milestones and royalties, plus a potential 50/50 profit share in the US, the company said. The company achieved a $20 million target in Q2 related to KT-485's preclinical progress and plans to begin phase 1 trials of KT-485 next year, aiming to treat immuno-inflammatory diseases more effectively.

Shares of Kymera were down more than 3% in recent Wednesday premarket activity.

Price: 45.50, Change: -1.64, Percent Change: -3.48